Dr. Frederick Locke, MD
Claim this profileMoffitt Cancer Center
Area of expertise
Cancer
Frederick Locke, MD has run 4 trials for Cancer. Some of their research focus areas include:
Diffuse Large B-Cell Lymphoma
Frederick Locke, MD has run 3 trials for Diffuse Large B-Cell Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Moffitt Cancer Center
H. Lee Moffitt Cancer Center & Research Institute
Clinical Trials Frederick Locke, MD is currently running
CAR T-Cell Preparation
for Cancer
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Recruiting
1 award
N/A
3 criteria
CAR-T Therapy
for Acute Lymphoblastic Leukemia
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
Recruiting
1 award
Phase 2
12 criteria
More about Frederick Locke, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Frederick Locke, MD has experience with
- CD19 Targeted CAR T Cell Therapy
- Pneumococcal Conjugate Vaccine (PCV13)
- Atezolizumab
- Immune Globulin Infusion (Human), 10% Solution
- Anti-CD19-targeting CAR-T Cells
- Cemacabtagene Ansegedleucel
Breakdown of trials Frederick Locke, MD has run
Cancer
Diffuse Large B-Cell Lymphoma
Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Frederick Locke, MD specialize in?
Frederick Locke, MD focuses on Cancer and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are T315I positive.
Is Frederick Locke, MD currently recruiting for clinical trials?
Yes, Frederick Locke, MD is currently recruiting for 8 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Frederick Locke, MD has studied deeply?
Yes, Frederick Locke, MD has studied treatments such as CD19 targeted CAR T Cell Therapy, Pneumococcal conjugate vaccine (PCV13), Atezolizumab.
What is the best way to schedule an appointment with Frederick Locke, MD?
Apply for one of the trials that Frederick Locke, MD is conducting.
What is the office address of Frederick Locke, MD?
The office of Frederick Locke, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.